-
Gene Therapy for Inherited Macular Degeneration Begins Pivotal Trial
18 Jul 2025 20:48 GMT
… trial. OCU410ST, which is being developed by Ocugen, is a possible treatment … with both age-related macular degeneration (AMD) and Stargardt … from Ocugen. The FDA has granted a Rare … #47;2 trial to treat dry age-related macular degeneration, according to …
-
Innovative Therapies Help Restore Vision Loss in Macular Degeneration
18 Jul 2025 20:36 GMT
… a dual-targeting drug currently in Phase III … in the LIGHTSITE III trial. Meanwhile, gene therapy … in the Treatment of Age-Related Macular Degeneration
Age-related macular degeneration (AMD … Numerous innovative drugs are presently under development to address …
-
Telomir Pharma Reports Positive Preclinical Data For Telomir-1; Stock Surges In Pre-market
18 Jul 2025 19:43 GMT
… Pharmaceuticals, Inc. (TELO) reported new positive preclinical results evaluating its lead drug … cancer cells, outperforming chemotherapy drug Paclitaxel or Rapamycin.
Studies … #39;s disease, age-related macular degeneration (AMD), autism spectrum disorder, …
-
Sanofi’s SAR446597 Granted FDA Fast Track for Geographic Atrophy in AMD
18 Jul 2025 14:59 GMT
… . Food and Drug Administration (FDA) has granted … treatment of geographic atrophy (GA) caused by age-related macular degeneration … (AMD). The fast track status is designed to accelerate the development … #47;2 clinical trial to evaluate the …
-
Mechanistic Insights into Shenzhuo Formula for Diabetic Retinopathy: Integrating UPLC-Q-TOF-MS/MS, Network Pharmacology, Single-Cell RNA Sequencing Data, and Experimental Validation
18 Jul 2025 12:58 GMT
… , various pharmacological agents have been developed, including … dose of the medication. This dosage was … therapeutic approaches in treating diabetic retinopathy. Inflammopharmacology … of age-related macular degeneration treatments trials. Ophthalmology. …
-
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
18 Jul 2025 11:02 GMT
… trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed … for approvals.” "Treating the first patient … with no approved treatment options. The encouraging … common form of inherited macular degeneration. The progressive vision …
-
US FDA grants fast track designation to Sanofi's SAR446597 to treat geographic atrophy due to age─related macular degeneration
17 Jul 2025 04:30 GMT
… US Food and Drug Administration (FDA) has granted fast … development and expedite the review of medicines to treat … FDA created this process to help deliver important new drugs … the treatment of patients with neovascular wet age-related macular degeneration.
…
-
Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast
16 Jul 2025 06:03 GMT
… medication over a period of months, providing steady treatment … related macular degeneration marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug … Inc.
Bayer AG
Neuraclegenetics
OliX Pharmaceuticals, Inc.
Ocular Therapeutix, Inc …
-
Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
16 Jul 2025 07:03 GMT
… US Food and Drug Administration (FDA) has granted fast … development and expedite the review of medicines to treat … FDA created this process to help deliver important new drugs … the treatment of patients with neovascular wet age-related macular degeneration.
…
-
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
16 Jul 2025 05:00 GMT
… Drug Administration (FDA … development and expedite the review of medicines to treat … FDA created this process to help deliver important new drugs … treatment of patients with neovascular wet age-related macular degeneration. About age-related macular degeneration …
About
© 1995-2025